Ilex Medical Ltd (TLV:ILX)
Israel
· Delayed Price · Currency is ILS · Price in ILA 5,529.00
-51.00 (-0.91%)
Apr 28, 2026, 5:24 PM IDT
Ilex Medical Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 930.83 | 920.37 | 916.25 | 863.28 | 1,061 | Upgrade
|
| Revenue Growth (YoY) | 1.14% | 0.45% | 6.13% | -18.63% | 12.10% | Upgrade
|
| Cost of Revenue | 718.95 | 704.06 | 689.34 | 580.37 | 681.61 | Upgrade
|
| Gross Profit | 211.88 | 216.31 | 226.9 | 282.91 | 379.38 | Upgrade
|
| Selling, General & Admin | 148.11 | 143.93 | 142.74 | 132.77 | 126.84 | Upgrade
|
| Research & Development | 7.97 | 7.62 | 6.85 | 5.89 | 8.35 | Upgrade
|
| Other Operating Expenses | - | 2 | -0.02 | -2.1 | -1.95 | Upgrade
|
| Operating Expenses | 156.08 | 153.54 | 149.56 | 136.56 | 133.24 | Upgrade
|
| Operating Income | 55.81 | 62.77 | 77.34 | 146.35 | 246.14 | Upgrade
|
| Interest Expense | -2.06 | -2.34 | -1.78 | -1.57 | -1.97 | Upgrade
|
| Interest & Investment Income | 7.53 | 7.85 | 5.74 | 1.86 | 1.86 | Upgrade
|
| Earnings From Equity Investments | -10.63 | -7.19 | -4.01 | -2.69 | -0.26 | Upgrade
|
| Currency Exchange Gain (Loss) | 9.12 | 0.22 | -5.23 | -10.27 | -1.59 | Upgrade
|
| Other Non Operating Income (Expenses) | 6.82 | -3.58 | -2.64 | -9.84 | 7.4 | Upgrade
|
| EBT Excluding Unusual Items | 66.58 | 57.73 | 69.43 | 123.85 | 251.58 | Upgrade
|
| Gain (Loss) on Sale of Investments | 7.43 | 4.32 | 4.37 | -2.72 | 3.78 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.13 | -0.46 | 0.24 | 21.96 | -0.01 | Upgrade
|
| Pretax Income | 74.14 | 61.6 | 74.04 | 143.09 | 255.35 | Upgrade
|
| Income Tax Expense | 18.58 | 15.89 | 18.51 | 34.6 | 57.87 | Upgrade
|
| Earnings From Continuing Operations | 55.56 | 45.7 | 55.53 | 108.49 | 197.48 | Upgrade
|
| Earnings From Discontinued Operations | - | -6.72 | -4.64 | -6.37 | - | Upgrade
|
| Net Income to Company | 55.56 | 38.98 | 50.89 | 102.12 | 197.48 | Upgrade
|
| Net Income | 55.56 | 38.98 | 50.89 | 102.12 | 197.48 | Upgrade
|
| Net Income to Common | 55.56 | 38.98 | 50.89 | 102.12 | 197.48 | Upgrade
|
| Net Income Growth | 42.52% | -23.39% | -50.17% | -48.29% | 63.72% | Upgrade
|
| Shares Outstanding (Basic) | 11 | 11 | 11 | 11 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 11 | 11 | 11 | 11 | Upgrade
|
| Shares Change (YoY) | - | -0.02% | -0.79% | -0.02% | 5.73% | Upgrade
|
| EPS (Basic) | 4.97 | 3.48 | 4.55 | 9.05 | 17.51 | Upgrade
|
| EPS (Diluted) | 4.97 | 3.48 | 4.55 | 9.05 | 17.50 | Upgrade
|
| EPS Growth | 42.52% | -23.34% | -49.80% | -48.27% | 55.66% | Upgrade
|
| Free Cash Flow | 45.89 | 51.87 | 31.66 | 43.6 | 229.73 | Upgrade
|
| Free Cash Flow Per Share | 4.10 | 4.64 | 2.83 | 3.87 | 20.36 | Upgrade
|
| Dividend Per Share | 1.986 | 1.220 | 1.365 | 1.917 | 5.319 | Upgrade
|
| Dividend Growth | 62.87% | -10.63% | -28.80% | -63.97% | - | Upgrade
|
| Gross Margin | 22.76% | 23.50% | 24.76% | 32.77% | 35.76% | Upgrade
|
| Operating Margin | 6.00% | 6.82% | 8.44% | 16.95% | 23.20% | Upgrade
|
| Profit Margin | 5.97% | 4.23% | 5.55% | 11.83% | 18.61% | Upgrade
|
| Free Cash Flow Margin | 4.93% | 5.64% | 3.46% | 5.05% | 21.65% | Upgrade
|
| EBITDA | 89.16 | 96.54 | 125.06 | 196.39 | 296.63 | Upgrade
|
| EBITDA Margin | 9.58% | 10.49% | 13.65% | 22.75% | 27.96% | Upgrade
|
| D&A For EBITDA | 33.36 | 33.77 | 47.72 | 50.04 | 50.49 | Upgrade
|
| EBIT | 55.81 | 62.77 | 77.34 | 146.35 | 246.14 | Upgrade
|
| EBIT Margin | 6.00% | 6.82% | 8.44% | 16.95% | 23.20% | Upgrade
|
| Effective Tax Rate | 25.06% | 25.80% | 25.00% | 24.18% | 22.66% | Upgrade
|
| Advertising Expenses | 3.32 | 3.53 | 3.64 | 3.4 | 1.4 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.